Study guide
9.6 Medication Adherence in Home and Outpatient Sterile Therapy
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
9.6 Medication Adherence in Home and Outpatient Sterile Therapy
Key Takeaways Explain This Topic AI
Adherence is how closely a patient's actual use matches the agreed regimen; persistence is how long therapy continues; primary nonadherence means therapy that is never started.
For sterile therapies given outside the hospital, objective adherence data come from ambulatory pump history logs, returned or unused doses, delivery records, and drug levels or other laboratory results.
Proportion of days covered (PDC) is days with medication available divided by days in the period; 80% or higher is the usual adherence threshold.
Common barriers include dosing frequency, device difficulty, adverse effects, cost, cognitive or physical limits, storage problems and low health literacy.
Effective interventions simplify the regimen (fewer doses, continuous infusion with suitable stability data, prefilled devices), use teach-back and motivational interviewing, involve caregivers, and monitor with follow-up calls and laboratory results.
Last updated: September 2026
9.6 Medication Adherence in Home and Outpatient Sterile Therapy
When sterile therapy moves home, the pharmacist no longer sees each dose given. Outpatient parenteral antimicrobial therapy (OPAT), home parenteral nutrition, continuous inotropes, pain pumps, self-injected biologics and oral-to-IV chemotherapy regimens all depend on the patient and caregiver. The BCSCP outline lists medication adherence (task 2B3) under therapeutic outcomes and monitoring. Missed or mistimed doses can cause treatment failure, antimicrobial resistance, readmission or line complications.
Key definitions
- Term Meaning
- Adherence How closely the patient's actual use matches the agreed regimen (dose, timing, technique)
- Persistence How long the patient keeps taking the therapy from start to discontinuation
Primary nonadherence Therapy that is prescribed but never started, for example a home infusion that never begins after discharge
- Compliance An older term implying passive obedience; "adherence" emphasizes a shared agreement
- Measuring adherence for sterile therapies
- Objective measures
Ambulatory pump history logs: Programmable home pumps record doses delivered, pauses, alarms and bolus requests. Review them at each nursing visit or cassette change.
Dose reconciliation: Compare doses delivered with doses used, and count unused or returned bags and syringes.
Delivery and refill records: Missed deliveries, or supplies building up in the home, suggest doses are being skipped.
Clinical markers: Drug levels (for example vancomycin), markers of infection (fever, inflammatory markers), and PN labs (glucose, electrolytes, weight trends).
Subjective measures include patient or caregiver report and structured questionnaires. They are easy to collect but tend to overestimate adherence.
Proportion of days covered (PDC) PDC = days with medication available days in the measurement period × 100 % \text{PDC} = \frac{\text{days with medication available}}{\text{days in the measurement period}} \times 100\% PDC = days in the measurement period days with medication available × 100%
Example: Deliveries covered 26 of the 30 days in a month, so PDC = 26 ÷ 30 = 86.7 % \text{PDC} = 26 \div 30 = 86.7\% PDC = 26 ÷ 30 = 86.7% . That is above the common 80% threshold used to call a patient adherent. The PDC shows supply, not actual use, so pump logs and clinical data are still needed.
Barriers specific to parenteral therapy
Barrier Example Intervention the pharmacist can design
Dosing frequency An every-8-hours antibiotic clashes with work and sleep A once-daily agent when clinically appropriate, or a continuous or programmed infusion from an ambulatory pump with stability data covering the reservoir interval
Device complexity Trouble programming, priming or connecting A simpler device (elastomeric, prefilled syringe), supervised practice, and teach-back
Adverse effects Nausea, infusion reactions, line discomfort Premedication plans, rate changes, prompt reporting
Storage and logistics No refrigerator space; deliveries missed Adjust delivery timing; ship validated coolers; choose products with longer BUDs
Cost and coverage High out-of-pocket costs; coverage limits Benefits investigation; financial assistance programs
Cognitive, sensory or physical limits Poor vision, tremor, memory problems Caregiver training, large-print labels, pump lockouts, nursing support
Health literacy Misunderstood instructions Plain-language materials, teach-back, pictorial guides
Beliefs and motivation "I feel better, so I can stop" Motivational interviewing; explain why the full course matters
How the compounding pharmacist influences adherence
Many adherence problems are solved at the compounding bench:
Regimen simplification through stability-supported continuous infusions in ambulatory pumps, or combining doses into one reservoir, only when the drug's stability over the full reservoir time and at body-proximate temperatures has been shown.
Ready-to-use formats , such as prefilled syringes and premixed bags, remove steps where patients make mistakes.
Delivery schedules and BUDs matched to the patient's routine.
Clear, consistent labels with the dose, the time and the storage instructions.
Counseling approaches
Teach-back for every critical step (see 9.3).
Motivational interviewing : open questions, reflective listening, and bringing out the patient's own reasons to continue.
Shared decision-making about the schedule and the device.
Structured follow-up : a call within 24 to 48 hours of starting home infusion, then at each delivery or visit.
Caregiver involvement when the patient cannot manage alone.
Closing the loop
Document the adherence findings, the barriers and the interventions. Tell the prescriber and the OPAT or nutrition support team when nonadherence threatens outcomes, for example when antibiotic doses are missed during treatment of endocarditis. Adherence data are also a quality measure, reviewed with readmissions and line infections.
Adherence issues by therapy type
OPAT antimicrobials: Missed or delayed doses can mean treatment failure in endocarditis or osteomyelitis, and they bring the risk of resistance. Weekly laboratory results, such as blood counts, renal function and vancomycin levels, double as adherence checks.
Home parenteral nutrition: Skipped or shortened cycles can cause dehydration, electrolyte problems and hypoglycemia after abrupt stops. Review weight, fluid balance and glucose logs with the PN order.
Continuous inotropes and pain pumps: Interruptions are dangerous. Teach how to handle alarms and bag changes, and give an after-hours number for pump failures.
Self-injected products (for example low-molecular-weight heparin or biologics): Check injection technique, storage and sharps disposal, and watch for injection-site reactions that lead patients to skip doses.
Warning signs of nonadherence include supplies piling up in the home, missed laboratory draws, repeated unacknowledged pump alarms, deliveries refused or rescheduled, and results that do not fit the prescribed regimen.